Results 101 to 110 of about 5,628,095 (258)

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

Parution : nouveau numéro de la Santander Art & Culture Law Review

open access: yes, 2018
Un nouveau numéro de Santander Art & Culture Law Review - revue polonaise spécialisée dans le droit de la culture et le droit de l'art - est paru durant l'été 2018 (numéroté 2/2017-3).
Droit, patrimoine & culture
core  

Participant 572 Community Conversations Written Interview

open access: yes, 2021
In this written interview, Participant 572 discusses challenges they faced during COVID-19, including supporting their children, navigating technology and a language barrier, and escaping a situation of abuse.
Anonymous
core  

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

open access: yesMolecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla   +9 more
wiley   +1 more source

Participant 578 Community Conversations Written Interview

open access: yes, 2021
In this written interview, Participant 578 shares that they have struggled financially during the COVID-19 pandemic because they could not find work. They share that isolation and having to stay at home were sources of stress.
Anonymous
core  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Written Arbitration Agreements – What Written Arbitration Agreements? [PDF]

open access: yes, 2013
First paragraph: This article considers the issue of an oral arbitration agreement in relation to the New York Convention. As Townsend once said "[a]rbitration offers a means to an end, and the end is to the resolution of disputes." This end would be ...
Yu, Hong-Lin
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy